Nasal spray vs. needle: which flu vaccine works better?

NCT ID NCT05921448

Ongoing Knowledge-focused Sponsor: Copenhagen Respiratory Research Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two flu vaccines: a nasal spray and a standard shot. Researchers will measure immune responses in the nose and blood of 60 healthy adults aged 18-49. The goal is to understand how each vaccine triggers protection and find ways to improve future flu vaccines.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Influenza vaccines (nasal spray and injection)
What this could lead to: If successful, this study could reveal which flu vaccine type triggers stronger nasal immunity, potentially leading to more effective vaccines.
What could go wrong: This is a very early, small study (60 people) focused on immune markers, not on preventing flu. Results may not apply to the general population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA, HUMAN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLUENZA, HUMAN

Contacts and locations

Locations

Copenhagen Hospital Biobank Unit, Department of Clinical Immunology, Rigshospitalet, Denmark

Copenhagen, Copenhagen, 2100, Denmark
Department of Medicine, Section of Respiratory Medicine, Herlev and Gentofte Hospital

Gentofte Municipality, Copenhagen, 2900, Denmark
Diagnostic Immunology, Department of Clinical Immunology, Rigshospitalet, Denmark

Copenhagen, Copenhagen, 2100, Denmark
Imperial College

London, W12 0NN, United Kingdom
Institute for Immunology and Microbiology (ISIM), Panum Institute, University of Copenhagen

Copenhagen, Copenhagen, 2100, Denmark
National Influenza Center for WHO at Statens Serum Institut (SSI)

Copenhagen, 2300, Denmark
Technical University of Denmark (DTU)

Kongens Lyngby, 2800, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.